SPRY - Latest News
ARS Pharmaceuticals, Inc. (SPRY), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $795.4M. Beta to the broader market is 0.80.
The article list below shows the most recent SPRY headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent SPRY Headlines
ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 15, 2026
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Q1 Earnings Call Highlights
marketbeat.com - May 15, 2026
ARS Pharmaceuticals NASDAQ: SPRY reported first-quarter 2026 revenue of $22. 7 million as executives said the company is working to expand access, red
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
zacks.com - May 15, 2026
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
globenewswire.com - May 15, 2026
Q1 2026 total revenue of $22. 7 million including neffy ® (epinephrine nasal spray) U.
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
benzinga.com - May 15, 2026
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.
How News Affects SPRY Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SPRY's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked SPRY news questions
- What is the latest SPRY news headline?
- The most recent SPRY headline (May 15, 2026) is "ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the SPRY news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What SPRY news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual SPRY options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.